Difference between revisions of "Interferon For Treatment of Melanoma"
Lakshmikantg (Talk | contribs) (→Search in Japanese database) |
Venkatram.a (Talk | contribs) |
||
(28 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==Dashboard== | ==Dashboard== | ||
− | * Click here to view '''[http:// | + | * Click here to view '''[http://www.dolcera.com/auth/dashboard/dashboard.php?workfile_id=891 Sample Dashboard]''' |
NOTE: You need to install Internet Explorer 8.0 and Adobe Flash Player to view the Dashboard. | NOTE: You need to install Internet Explorer 8.0 and Adobe Flash Player to view the Dashboard. | ||
Line 53: | Line 53: | ||
==Concept Table== | ==Concept Table== | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | ||
Line 89: | Line 89: | ||
|} | |} | ||
===French Keywords Concept table=== | ===French Keywords Concept table=== | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | ||
Line 123: | Line 123: | ||
===German Keywords Concept Table=== | ===German Keywords Concept Table=== | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center> | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center> | ||
Line 170: | Line 170: | ||
* '''Relevant IPC classes''' | * '''Relevant IPC classes''' | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC''' | |align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Sr. No.''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class Code''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class definition''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class coverage''' |
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''1''' |
|align = "center"|A61K003819 | |align = "center"|A61K003819 | ||
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | |align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | ||
|align = "center"|Broad | |align = "center"|Broad | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''2''' |
|align = "center"|A61K003821 | |align = "center"|A61K003821 | ||
|align = "center"|Medicinal preparations containing peptides Interferon | |align = "center"|Medicinal preparations containing peptides Interferon | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''3''' |
|align = "center"|C07K001452 | |align = "center"|C07K001452 | ||
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | |align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | ||
|align = "center"|Broad | |align = "center"|Broad | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''4''' |
|align = "center"|C07K014555 | |align = "center"|C07K014555 | ||
|align = "center"|Peptides having more than 20 amino acids - Interferon | |align = "center"|Peptides having more than 20 amino acids - Interferon | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''5''' |
|align = "center"|C07K001456 | |align = "center"|C07K001456 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha | |align = "center"|Peptides having more than 20 amino acids - IFN-alpha | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''6''' |
|align = "center"|C07K014565 | |align = "center"|C07K014565 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-beta | |align = "center"|Peptides having more than 20 amino acids - IFN-beta | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''7''' |
|align = "center"|C07K001457 | |align = "center"|C07K001457 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma | |align = "center"|Peptides having more than 20 amino acids - IFN-gamma | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''8''' |
|align = "center"|A61P003500 | |align = "center"|A61P003500 | ||
|align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents | |align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents | ||
Line 222: | Line 222: | ||
* '''Relevant ECLA classes''' | * '''Relevant ECLA classes''' | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA''' | |align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Sr. No.''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class Code''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class definition''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class coverage''' |
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''1''' |
|align = "center"|A61K003819 | |align = "center"|A61K003819 | ||
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | |align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | ||
|align = "center"|Broad | |align = "center"|Broad | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''2''' |
|align = "center"|A61K003821 | |align = "center"|A61K003821 | ||
|align = "center"|Medicinal preparations containing Interferon | |align = "center"|Medicinal preparations containing Interferon | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''3''' |
|align = "center"|A61K38/21A | |align = "center"|A61K38/21A | ||
|align = "center"|Medicinal preparations containing IFN-alpha | |align = "center"|Medicinal preparations containing IFN-alpha | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''4''' |
|align = "center"|A61K38/21B | |align = "center"|A61K38/21B | ||
|align = "center"|Medicinal preparations containing IFN-beta | |align = "center"|Medicinal preparations containing IFN-beta | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''5''' |
|align = "center"|A61K38/21C | |align = "center"|A61K38/21C | ||
|align = "center"|Medicinal preparations containing IFN-gamma | |align = "center"|Medicinal preparations containing IFN-gamma | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''6''' |
|align = "center"|C07K001452 | |align = "center"|C07K001452 | ||
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | |align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | ||
|align = "center"|Broad | |align = "center"|Broad | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''7''' |
|align = "center"|C07K014555 | |align = "center"|C07K014555 | ||
|align = "center"|Peptides having more than 20 amino acids - Interferon | |align = "center"|Peptides having more than 20 amino acids - Interferon | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''8''' |
|align = "center"|C07K001456 | |align = "center"|C07K001456 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha | |align = "center"|Peptides having more than 20 amino acids - IFN-alpha | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''9''' |
|align = "center"|C07K014565 | |align = "center"|C07K014565 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-beta | |align = "center"|Peptides having more than 20 amino acids - IFN-beta | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''10''' |
|align = "center"|C07K001457 | |align = "center"|C07K001457 | ||
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma | |align = "center"|Peptides having more than 20 amino acids - IFN-gamma | ||
|align = "center"|Specific | |align = "center"|Specific | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''11''' |
|align = "center"|C07K014715G | |align = "center"|C07K014715G | ||
|align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons - | |align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons - | ||
Line 289: | Line 289: | ||
* '''Relevant US classes''' | * '''Relevant US classes''' | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class''' | |align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Sr. No.''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class Code''' |
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''Class definition''' |
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''1''' |
|align = "center"|4240854 | |align = "center"|4240854 | ||
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible | |align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''2''' |
|align = "center"|4242811 | |align = "center"|4242811 | ||
|align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.) | |align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.) | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''3''' |
|align = "center"|42400141 | |align = "center"|42400141 | ||
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof | |align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''4''' |
|align = "center"|514889 | |align = "center"|514889 | ||
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER | |align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''5''' |
|align = "center"|530351 | |align = "center"|530351 | ||
|align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc. | |align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc. | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''6''' |
|align = "center"|930142 | |align = "center"|930142 | ||
|align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon | |align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''7''' |
|align = "center"|4240851 | |align = "center"|4240851 | ||
|align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines) | |align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines) | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''8''' |
|align = "center"|4240855 | |align = "center"|4240855 | ||
|align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon. | |align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon. | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''9''' |
|align = "center"|4240856 | |align = "center"|4240856 | ||
|align = "center"|Subject matter in which the interferon is beta or fibroblast interferon. | |align = "center"|Subject matter in which the interferon is beta or fibroblast interferon. | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99ccff"|'''10''' |
|align = "center"|4240857 | |align = "center"|4240857 | ||
|align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon. | |align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon. | ||
Line 350: | Line 350: | ||
{|border="2" cellspacing="0" cellpadding="4" width="100%" | {|border="2" cellspacing="0" cellpadding="4" width="100%" | ||
− | |align = "center" bgcolor = "#99CCFF"|''' | + | |align = "center" bgcolor = "#99CCFF"|'''S.No.''' |
|align = "center" bgcolor = "#99CCFF"|'''Search concept''' | |align = "center" bgcolor = "#99CCFF"|'''Search concept''' | ||
|align = "center" bgcolor = "#99CCFF"|'''Search Scope''' | |align = "center" bgcolor = "#99CCFF"|'''Search Scope''' | ||
Line 358: | Line 358: | ||
|align = "center" bgcolor = "#99CCFF"|'''No. of hits''' | |align = "center" bgcolor = "#99CCFF"|'''No. of hits''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''1''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title, Abstract and Claims | |align = "center"|Title, Abstract and Claims | ||
Line 366: | Line 366: | ||
|align = "center"|576 | |align = "center"|576 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''2''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title, Abstract and Claims | |align = "center"|Title, Abstract and Claims | ||
Line 374: | Line 374: | ||
|align = "center"|756 | |align = "center"|756 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''3''' |
|align = "center"|'''Final query''' | |align = "center"|'''Final query''' | ||
|align = "center" colspan = "4"|'''1 OR 2''' | |align = "center" colspan = "4"|'''1 OR 2''' | ||
Line 387: | Line 387: | ||
{|border="2" cellspacing="0" cellpadding="4" align = "center" width="100%" | {|border="2" cellspacing="0" cellpadding="4" align = "center" width="100%" | ||
− | |align = "center" bgcolor = "#99CCFF"|''' | + | |align = "center" bgcolor = "#99CCFF"|'''S.No.''' |
|align = "center" bgcolor = "#99CCFF"|'''Search concept''' | |align = "center" bgcolor = "#99CCFF"|'''Search concept''' | ||
|align = "center" bgcolor = "#99CCFF"|'''Language''' | |align = "center" bgcolor = "#99CCFF"|'''Language''' | ||
Line 426: | Line 426: | ||
|- | |- | ||
|} | |} | ||
− | |||
===Search in Micropatent MPI-INPADOC - English language search=== | ===Search in Micropatent MPI-INPADOC - English language search=== | ||
Line 433: | Line 432: | ||
{|border="2" cellspacing="0" cellpadding="4" width="100%" | {|border="2" cellspacing="0" cellpadding="4" width="100%" | ||
− | |align = "center" bgcolor = "#99CCFF"|''' | + | |align = "center" bgcolor = "#99CCFF"|'''S.No.''' |
|align = "center" bgcolor = "#99CCFF"|'''Search concept''' | |align = "center" bgcolor = "#99CCFF"|'''Search concept''' | ||
|align = "center" bgcolor = "#99CCFF"|'''Search Scope''' | |align = "center" bgcolor = "#99CCFF"|'''Search Scope''' | ||
Line 441: | Line 440: | ||
|align = "center" bgcolor = "#99CCFF"|'''No. of hits''' | |align = "center" bgcolor = "#99CCFF"|'''No. of hits''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''1''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title and Abstract | |align = "center"|Title and Abstract | ||
Line 449: | Line 448: | ||
|align = "center"|174 | |align = "center"|174 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''2''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title and Abstract | |align = "center"|Title and Abstract | ||
Line 457: | Line 456: | ||
|align = "center"|484 | |align = "center"|484 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''3''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title and Abstract | |align = "center"|Title and Abstract | ||
Line 465: | Line 464: | ||
|align = "center"|102 | |align = "center"|102 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''4''' |
|align = "center"|Interferon for treating Melanoma | |align = "center"|Interferon for treating Melanoma | ||
|align = "center"|Title and Abstract | |align = "center"|Title and Abstract | ||
Line 473: | Line 472: | ||
|align = "center"|9 | |align = "center"|9 | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''5''' |
|align = "center" colspan = "4"|'''Final query''' | |align = "center" colspan = "4"|'''Final query''' | ||
|align = "center"|'''1 OR 2 OR 3 OR 4''' | |align = "center"|'''1 OR 2 OR 3 OR 4''' | ||
Line 485: | Line 484: | ||
{|border="2" cellspacing="0" cellpadding="4" width="100%" | {|border="2" cellspacing="0" cellpadding="4" width="100%" | ||
− | |align = "center" bgcolor = "#99CCFF"|''' | + | |align = "center" bgcolor = "#99CCFF"|'''S.No.''' |
|align = "center" bgcolor = "#99CCFF"|'''Search concept''' | |align = "center" bgcolor = "#99CCFF"|'''Search concept''' | ||
|align = "center" bgcolor = "#99CCFF"|'''Language''' | |align = "center" bgcolor = "#99CCFF"|'''Language''' | ||
Line 529: | Line 528: | ||
Database: IPDL (Industrial property digital library), Japan | Database: IPDL (Industrial property digital library), Japan | ||
− | Date of search: 1900/01/01 to | + | Date of search: 1900/01/01 to 2011/02/15 |
− | {| border="2" cellspacing="0" cellpadding="4" align = " | + | {| border="2" cellspacing="0" cellpadding="4" align = "left" width="100%" |
| style="background-color:#99ccff;padding:0.079cm;"| '''S.No.''' | | style="background-color:#99ccff;padding:0.079cm;"| '''S.No.''' | ||
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''Issue/Publication date'''</center> | | style="background-color:#99ccff;padding:0.079cm;"| <center>'''Issue/Publication date'''</center> | ||
Line 540: | Line 539: | ||
|- | |- | ||
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''1'''</center> | | style="background-color:#99ccff;padding:0.079cm;"| <center>'''1'''</center> | ||
− | | style="padding:0.079cm;"| <center>''' | + | | style="padding:0.079cm;"| <center>'''1900/01/01 to 2011/02/15'''</center> |
− | | style="padding:0.079cm;"| <center> | + | | style="padding:0.079cm;"| <center>4H045</center> |
− | | style="padding:0.079cm;"| <center> | + | | style="padding:0.079cm;"| <center>DA15+DA16+DA17+DA18 </center> |
− | | style="padding:0.079cm;"| <center> | + | | style="padding:0.079cm;"| <center>1298</center> |
|} | |} | ||
+ | <br> | ||
+ | |||
+ | |||
+ | '''Total patents: 1298 (Relevancy ~10%)''' | ||
− | |||
* '''F-Terms and theme used in search''' | * '''F-Terms and theme used in search''' | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search''' | |align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search''' | ||
|align = "center" bgcolor = "#99CCFF"|'''Definition''' | |align = "center" bgcolor = "#99CCFF"|'''Definition''' | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''Sr. No.''' |
|align = "center"|'''F- Term theme''' | |align = "center"|'''F- Term theme''' | ||
|align = "center"|'''4H045''' | |align = "center"|'''4H045''' | ||
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof | |align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''1''' |
|align = "center"|F-term | |align = "center"|F-term | ||
|align = "center"|DA15 | |align = "center"|DA15 | ||
|align = "center"|Peptide or protein characterised by function - Interferons | |align = "center"|Peptide or protein characterised by function - Interferons | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''2''' |
|align = "center"|F-term | |align = "center"|F-term | ||
|align = "center"|DA16 | |align = "center"|DA16 | ||
|align = "center"|Alpha-interferons | |align = "center"|Alpha-interferons | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''3''' |
|align = "center"|F-term | |align = "center"|F-term | ||
|align = "center"|DA17 | |align = "center"|DA17 | ||
|align = "center"|Beta-interferons | |align = "center"|Beta-interferons | ||
|- | |- | ||
− | |align = "center" bgcolor = "# | + | |align = "center" bgcolor = "#99CCFF"|'''4''' |
|align = "center"|F-term | |align = "center"|F-term | ||
|align = "center"|DA18 | |align = "center"|DA18 | ||
Line 585: | Line 587: | ||
===Scientific Literature Search=== | ===Scientific Literature Search=== | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>S.No</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>S.No</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Database</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Database</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Query</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Query</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Limits by Date</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Limits by Date</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>No.Of Hits</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>No.Of Hits</b></center> |
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>1</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>1</b></center> |
| style="padding:0.079cm;"| <center>Pubmed</center> | | style="padding:0.079cm;"| <center>Pubmed</center> | ||
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | | style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | ||
Line 600: | Line 602: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>2</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>2</b></center> |
| style="padding:0.079cm;"| <center>Scirus</center> | | style="padding:0.079cm;"| <center>Scirus</center> | ||
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | | style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | ||
Line 607: | Line 609: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>3</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>3</b></center> |
| style="padding:0.079cm;"| <center>Google Scholar</center> | | style="padding:0.079cm;"| <center>Google Scholar</center> | ||
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | | style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center> | ||
Line 629: | Line 631: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''1'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''1'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US7482014B2</center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7482014.PN.&OS=PN/7482014&RS=PN/7482014 US7482014B2]</center> |
| style=";padding:0.079cm;"| <center>01/27/2009</center> | | style=";padding:0.079cm;"| <center>01/27/2009</center> | ||
| style=";padding:0.079cm;"| <center>Schering Corporation</center> | | style=";padding:0.079cm;"| <center>Schering Corporation</center> | ||
Line 639: | Line 641: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''2'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''2'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US5997858A</center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5997858.PN.&OS=PN/5997858&RS=PN/5997858 US5997858A]</center> |
| style=";padding:0.079cm;"| <center>12/7/1999</center> | | style=";padding:0.079cm;"| <center>12/7/1999</center> | ||
| style=";padding:0.079cm;"| <center>Pharma Pacific Pty Ltd.</center> | | style=";padding:0.079cm;"| <center>Pharma Pacific Pty Ltd.</center> | ||
Line 649: | Line 651: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''3'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''3'''</center> | ||
− | | style=";padding:0.079cm;"| <center>EP288055A1</center> | + | | style=";padding:0.079cm;"| <center>[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19881026&CC=EP&NR=0288055A1&KC=A1 EP288055A1]</center> |
| style=";padding:0.079cm;"| <center>10/26/1988</center> | | style=";padding:0.079cm;"| <center>10/26/1988</center> | ||
| style=";padding:0.079cm;"| <center>MERRELL DOW PHARMACEUTICALS INC.</center> | | style=";padding:0.079cm;"| <center>MERRELL DOW PHARMACEUTICALS INC.</center> | ||
Line 659: | Line 661: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''4'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''4'''</center> | ||
− | | style=";padding:0.079cm;"| <center>EP241242A1</center> | + | | style=";padding:0.079cm;"| <center>[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19871014&CC=EP&NR=0241242A1&KC=A1 EP241242A1]</center> |
| style=";padding:0.079cm;"| <center>10/14/1987</center> | | style=";padding:0.079cm;"| <center>10/14/1987</center> | ||
| style=";padding:0.079cm;"| <center>CETUS ONCOLOGY CORPORATION</center> | | style=";padding:0.079cm;"| <center>CETUS ONCOLOGY CORPORATION</center> | ||
Line 669: | Line 671: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''5'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''5'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US20100086518 </center> | + | | style=";padding:0.079cm;"| <center>[http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100086518%22.PGNR.&OS=DN/20100086518&RS=DN/20100086518 US20100086518] </center> |
| style=";padding:0.079cm;"| <center>4/8/2010</center> | | style=";padding:0.079cm;"| <center>4/8/2010</center> | ||
| style=";padding:0.079cm;"| <center>NOVARTIS AG</center> | | style=";padding:0.079cm;"| <center>NOVARTIS AG</center> | ||
Line 679: | Line 681: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''6'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''6'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US4846782 </center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4846782.PN.&OS=PN/4846782&RS=PN/4846782 US4846782] </center> |
| style=";padding:0.079cm;"| <center>7/11/1989</center> | | style=";padding:0.079cm;"| <center>7/11/1989</center> | ||
| style=";padding:0.079cm;"| <center>Schering Corporation</center> | | style=";padding:0.079cm;"| <center>Schering Corporation</center> | ||
Line 689: | Line 691: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''7'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''7'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US5824300 </center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5824300.PN.&OS=PN/5824300&RS=PN/5824300 US5824300] </center> |
| style=";padding:0.079cm;"| <center>10/20/1998</center> | | style=";padding:0.079cm;"| <center>10/20/1998</center> | ||
| style=";padding:0.079cm;"| <center>The Texas A&M University System</center> | | style=";padding:0.079cm;"| <center>The Texas A&M University System</center> | ||
Line 699: | Line 701: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''8'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''8'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US20020107184</center> | + | | style=";padding:0.079cm;"| <center>[http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220020107184%22.PGNR.&OS=DN/20020107184&RS=DN/20020107184 US20020107184]</center> |
| style=";padding:0.079cm;"| <center>8/8/2002</center> | | style=";padding:0.079cm;"| <center>8/8/2002</center> | ||
| style=";padding:0.079cm;"| <center>None</center> | | style=";padding:0.079cm;"| <center>None</center> | ||
Line 709: | Line 711: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''9'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''9'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US4762705 </center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4762705.PN.&OS=PN/4762705&RS=PN/4762705 US4762705] </center> |
| style=";padding:0.079cm;"| <center>8/9/1988</center> | | style=";padding:0.079cm;"| <center>8/9/1988</center> | ||
| style=";padding:0.079cm;"| <center>Schwimmer, Adolf W. | Schwartz, Irwin Steven | Rubin, David</center> | | style=";padding:0.079cm;"| <center>Schwimmer, Adolf W. | Schwartz, Irwin Steven | Rubin, David</center> | ||
Line 719: | Line 721: | ||
|- | |- | ||
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''10'''</center> | | style="background-color:#99ccff;;padding:0.079cm;"| <center>'''10'''</center> | ||
− | | style=";padding:0.079cm;"| <center>US5190751 </center> | + | | style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5190751.PN.&OS=PN/5190751&RS=PN/5190751 US5190751] </center> |
| style=";padding:0.079cm;"| <center>3/2/1993</center> | | style=";padding:0.079cm;"| <center>3/2/1993</center> | ||
| style=";padding:0.079cm;"| <center>Schering Corporation</center> | | style=";padding:0.079cm;"| <center>Schering Corporation</center> | ||
Line 747: | Line 749: | ||
4 : Published Patent & Focus in Dependent claim <br> | 4 : Published Patent & Focus in Dependent claim <br> | ||
− | {|border="2" cellspacing="0" cellpadding="4" width=" | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>S.No</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>S.No</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Patent</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Patent</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Type</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Type</b></center> |
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>Patent Ranking</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>Patent Ranking</b></center> |
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>1</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>1</b></center> |
| style="padding:0.079cm;"| <center>US7482014B2</center> | | style="padding:0.079cm;"| <center>US7482014B2</center> | ||
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | ||
Line 760: | Line 762: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>2</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>2</b></center> |
| style="padding:0.079cm;"| <center>US5997858A</center> | | style="padding:0.079cm;"| <center>US5997858A</center> | ||
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | ||
Line 766: | Line 768: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>3</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>3</b></center> |
| style="padding:0.079cm;"| <center>EP288055A1</center> | | style="padding:0.079cm;"| <center>EP288055A1</center> | ||
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | ||
Line 772: | Line 774: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>4</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>4</b></center> |
| style="padding:0.079cm;"| <center>EP241242A1</center> | | style="padding:0.079cm;"| <center>EP241242A1</center> | ||
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | ||
Line 778: | Line 780: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>5</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>5</b></center> |
| style="padding:0.079cm;"| <center>US20100086518 </center> | | style="padding:0.079cm;"| <center>US20100086518 </center> | ||
| style="padding:0.079cm;"| <center>Published And Dependent</center> | | style="padding:0.079cm;"| <center>Published And Dependent</center> | ||
Line 784: | Line 786: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>6</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>6</b></center> |
| style="padding:0.079cm;"| <center>US4846782 </center> | | style="padding:0.079cm;"| <center>US4846782 </center> | ||
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | ||
Line 790: | Line 792: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>7</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>7</b></center> |
| style="padding:0.079cm;"| <center>US5824300 </center> | | style="padding:0.079cm;"| <center>US5824300 </center> | ||
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Dependent Claim</center> | ||
Line 796: | Line 798: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>8</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>8</b></center> |
| style="padding:0.079cm;"| <center>US20020107184</center> | | style="padding:0.079cm;"| <center>US20020107184</center> | ||
| style="padding:0.079cm;"| <center>Published And Independent</center> | | style="padding:0.079cm;"| <center>Published And Independent</center> | ||
Line 802: | Line 804: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>9</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>9</b></center> |
| style="padding:0.079cm;"| <center>US4762705 </center> | | style="padding:0.079cm;"| <center>US4762705 </center> | ||
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | ||
Line 808: | Line 810: | ||
|- | |- | ||
− | | style="background-color:#99ccff;padding:0.079cm;"| <center>10</center> | + | | style="background-color:#99ccff;padding:0.079cm;"| <center><b>10</b></center> |
| style="padding:0.079cm;"| <center>US5190751 </center> | | style="padding:0.079cm;"| <center>US5190751 </center> | ||
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | | style="padding:0.079cm;"| <center>Granted And Independent Claim</center> | ||
Line 931: | Line 933: | ||
===Global Revenue Data Of products=== | ===Global Revenue Data Of products=== | ||
− | + | {|border="2" cellspacing="0" cellpadding="4" width="100%" | |
− | + | |bgcolor = "#99ccff" rowspan = "2"|'''S.No''' | |
− | + | |bgcolor = "#99ccff" rowspan = "2"|''' Generic Name''' | |
− | + | |bgcolor = "#99ccff" rowspan = "2"|''' Brand Name''' | |
− | + | |bgcolor = "#99ccff" rowspan = "2"|''' Company''' | |
− | + | |bgcolor = "#99ccff" colspan = "3"|''' Global revenue ($ Million )''' | |
− | + | |- | |
− | + | |align = "right" bgcolor = "#C5D9F1"|'''2008''' | |
− | + | |align = "right" bgcolor = "#C5D9F1"|'''2009''' | |
− | + | |align = "right" bgcolor = "#C5D9F1"|'''2010''' | |
− | + | |- | |
− | + | |bgcolor = "#99ccff"|'''1''' | |
− | + | | Alpha IFN | |
− | + | | Intron®,Roferon®-A | |
− | + | |Schering Corporation | |
− | + | |align = "right"| | |
− | + | |align = "right"| 38.4 2 | |
− | + | |align = "right"| | |
− | + | |- | |
− | + | |bgcolor = "#99ccff"|'''2''' | |
− | + | | Beta IFN | |
− | + | | Avonex | |
− | + | |Biogen IDEC | |
− | + | |align = "right"|2518.4 | |
− | + | |align = "right"|2322.9 | |
− | + | |align = "right"| 2202.6 3 | |
− | + | |- | |
− | + | |bgcolor = "#99ccff"|'''3''' | |
− | + | | Gamma IFN | |
− | + | | Actimmune® | |
− | + | | Intermune | |
− | + | |align = "right"|29880 | |
− | + | |align = "right"| 25428 4 | |
− | + | |align = "right"| | |
− | + | |- | |
− | + | |bgcolor = "#99ccff"|'''4''' | |
− | + | | Pegylated IFN | |
− | + | | Peg Intron | |
− | + | | Schering-Plough | |
− | + | |align = "right"| | |
− | + | |align = "right"| 148.7 5 | |
− | + | |align = "right"| | |
− | + | |- | |
− | + | |bgcolor = "#99ccff"|'''5''' | |
− | + | | Recombinant IFN | |
− | + | |Rebetron®, Rebetol® | |
− | + | | Schering Corporation | |
− | + | |align = "right"| | |
− | + | |align = "right"|36.1 | |
− | + | |align = "right"| | |
− | + | |- | |
− | + | |} | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
==Biosimilars Of Interferons== | ==Biosimilars Of Interferons== |
Latest revision as of 00:07, 7 September 2018
Contents
- 1 Dashboard
- 2 Objective
- 3 Overview
- 4 Interactive Taxonomy
- 5 Concept Table
- 6 Intellectual property
- 6.1 Search strategy and concept
- 6.2 Search in Micropatent full text - English language search
- 6.3 Search in Micropatent full text - Foreign language search
- 6.4 Search in Micropatent MPI-INPADOC - English language search
- 6.5 Search in Micropatent MPI-INPADOC - Foreign language search
- 6.6 Search in Japanese database
- 6.7 Scientific Literature Search
- 7 Sample patents
- 8 Taxonomy
- 9 Sample Analysis
- 10 Patent Ranking
- 11 Clinical Trials
- 12 IP Activity Graphs Of Sample Patents
- 13 Market Report
- 14 Biosimilars Of Interferons
Dashboard
- Click here to view Sample Dashboard
NOTE: You need to install Internet Explorer 8.0 and Adobe Flash Player to view the Dashboard.
Please download Internet Explorer 8.0 and Adobe Flash player
Objective
Primary objective of the study was to perform a prior art search on usage of interferon for the treatment of melanoma.
To achieve our objective we performed following steps:
- Created a multi level taxonomy to categorize the patents using interferon for melanoma treatment
- Marked out relevant IPC, ECLA, US classes and Japanese F-term available for technology in question.
- Identified and clubbed relevant keywords with classes to extract relevant patents.
- Checked for patents in US, EP, PCT, JP, Great Britain, and German patent records
- Performed MPI-INPADOC search which cover bibliographic data for 71 countries and legal status for 42 countries
- Analyzed the patents and prepared an IPmap covering relevant patents for client usage.
Overview
Interferon
![](/wiki/images/Interferon.jpg)
Interferons (IFNs) are natural cell-signaling proteins produced by the cells of the immune system of most vertebrates in response to challenges such as viruses, parasites and tumor cells. They belong to the large class of glycoproteins known as cytokines and are produced by a wide variety of cells in response to the presence of double-stranded RNA, a key indicator of viral infection. Source
Interferons assist the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to T lymphocytes, and increasing the resistance of host cells to viral infection. There are 3 known classes of interferons; type I, type II and type III. All classes are very important in fighting viral infections. Recent studies have shown that Interferon can also help stop the growth and spread of cancer cells. Source
Melanoma
Melanoma is the most serious type of skin cancer. It begins in skin cells called melanocytes. Melanocytes are the cells that make melanin, which gives skin its color. Melanin also protects the deeper layers of the skin from the sun's harmful ultraviolet (UV) rays.When people spend time in the sunlight, the melanocytes make more melanin and cause the skin to tan. This also happens when skin is exposed to other forms of ultraviolet light (such as in a tanning booth). If the skin receives too much ultraviolet light, the melanocytes may begin to grow abnormally and become cancerous. This condition is called melanoma.People with melanoma who have one or more positive lymph nodes are at a high risk to have their melanoma recur. It is believed that 70 to 80% of these individuals will have their melanoma come back within the next three to five years. Source
Interferon for treatment of melanoma
Over the past several decades, the incidence of melanoma has increased at a faster rate than that of any other solid tumor. In the 1930s, the lifetime risk for a person living in the U.S. to develop melanoma was 1 in 1,500. Currently, that risk is 1 in 74, and for 2003 it was estimated that 51,400 cases of invasive melanoma would be diagnosed. While efforts to improve early diagnosis through education have resulted in the increased detection of early-stage melanoma, many patients still present with high-risk primary melanomas.
A beacon of hope in the treatment of melanoma has long been the observation that melanoma is susceptible to attack by the host’s immune system. This has resulted in the testing of a remarkably broad spectrum of immunotherapies, including the use of nonspecific immunostimulants, various approaches to vaccine therapies, and cytokine therapy. Many of these approaches failed to demonstrate a significant clinical impact, and the practitioner had been left with few options in treating high-risk melanoma patients with adjuvant therapy. One exception to this, however, has been the use of adjuvant interferon alpha (IFN-{alpha})
While the precise mechanism of action remains poorly understood, there are multiple antitumor effects of IFN-{alpha}. These include a direct antiproliferative effect, the enhancement of natural killer cell activity, and the upregulation of tumor antigens and/or HLA class I and class II antigens. Initial phase II clinical studies with IFN-{alpha} in metastatic melanoma showed response rates in the 10%–20% range [4, 5]. These response rates, while encouraging, were not significant enough to lead to its widespread use in the treatment of metastatic melanoma. Source
Interactive Taxonomy
Concept Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
French Keywords Concept table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
German Keywords Concept Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class codes identified for searches
- Relevant IPC classes
IPC | |||
Sr. No. | Class Code | Class definition | Class coverage |
1 | A61K003819 | Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | Broad |
2 | A61K003821 | Medicinal preparations containing peptides Interferon | Specific |
3 | C07K001452 | Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | Broad |
4 | C07K014555 | Peptides having more than 20 amino acids - Interferon | Specific |
5 | C07K001456 | Peptides having more than 20 amino acids - IFN-alpha | Specific |
6 | C07K014565 | Peptides having more than 20 amino acids - IFN-beta | Specific |
7 | C07K001457 | Peptides having more than 20 amino acids - IFN-gamma | Specific |
8 | A61P003500 | Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents | Broad |
- Relevant ECLA classes
ECLA | |||
Sr. No. | Class Code | Class definition | Class coverage |
1 | A61K003819 | Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons | Broad |
2 | A61K003821 | Medicinal preparations containing Interferon | Specific |
3 | A61K38/21A | Medicinal preparations containing IFN-alpha | Specific |
4 | A61K38/21B | Medicinal preparations containing IFN-beta | Specific |
5 | A61K38/21C | Medicinal preparations containing IFN-gamma | Specific |
6 | C07K001452 | Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons | Broad |
7 | C07K014555 | Peptides having more than 20 amino acids - Interferon | Specific |
8 | C07K001456 | Peptides having more than 20 amino acids - IFN-alpha | Specific |
9 | C07K014565 | Peptides having more than 20 amino acids - IFN-beta | Specific |
10 | C07K001457 | Peptides having more than 20 amino acids - IFN-gamma | Specific |
11 | C07K014715G | Receptors; Cell surface antigens; Cell surface determinants - for interferons - | Specific |
- Relevant US classes
US class | ||
Sr. No. | Class Code | Class definition |
1 | 4240854 | DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible |
2 | 4242811 | DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.) |
3 | 42400141 | DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof |
4 | 514889 | DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER |
5 | 530351 | CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc. |
6 | 930142 | PEPTIDE OR PROTEIN SEQUENCE - Interferon |
7 | 4240851 | LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines) |
8 | 4240855 | Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon. |
9 | 4240856 | Subject matter in which the interferon is beta or fibroblast interferon. |
10 | 4240857 | Subject matter in which the interferon is alpha or leukocyte interferon. |
Intellectual property
Search strategy and concept
Date of Search: 1836 to Feb 3rd, 2011 Database used: Micropatent - Include extensive full text and MPI-Inpadoc searches
Search in Micropatent full text - English language search
Micro patent full text search allow search in fulltext of US, EP, PCT, Great Britain, and German patent records as well as the front page of JP documents. US, EP, and DE are covered at first publication and when granted.
S.No. | Search concept | Search Scope | Search reason | Class Code (IPC,US,ECLA) | Search query | No. of hits |
1 | Interferon for treating Melanoma | Title, Abstract and Claims | Specific classes of interferon AND melanoma keywords | A61K003821* OR C07K014555 OR C07K001456 OR C07K014565 OR C07K001457 OR C07K014715G OR 4240854 OR 4242811 OR 42400141 OR 514889 OR 530351 OR 930142 | (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 576 |
2 | Interferon for treating Melanoma | Title, Abstract and Claims | Broad classes of interferon AND melanoma, interferon keywords | A61K003819 OR C07K001452 OR 4240851 OR 4240855 OR 4240856 OR 4240857 OR A61P003500 | (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 756 |
3 | Final query | 1 OR 2 | 1019 records 571 unique records |
Search in Micropatent full text - Foreign language search
Micro patent full text search allow search in fulltext of US, EP, PCT, Great Britain, and German patent records as well as the front page of JP documents. US, EP, and DE are covered at first publication and when granted.
S.No. | Search concept | Language | Search Scope | Search reason | Class Code (IPC, ECLA) | Search query | No. of hits |
1 | Interferon for treating Melanoma | French | Title, Abstract and Claims | Specific classes of interferon AND melanoma’s foregin langugae keywords | A61K003821* OR C07K014555 OR C07K001456 OR C07K014565 OR C07K001457 OR C07K014715G | (mélanome or (Peau NEAR3 (Cancer or Carcinome or Tumeur)) OR (Mélanocytes Near3 (Cancer or Carcinome or Tumeur))) | 184 hits |
German | (Melanom or (Haut NEAR3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst)) OR (Melanozyten Near3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst))) | ||||||
2 | Interferon for treating Melanoma | French | Title, Abstract and Claims | Broad classes of interferon AND melanoma’s and interferon’s foregin langugae keywords | A61K003819 OR C07K001452 OR A61P003500 | (mélanome or (Peau NEAR3 (Cancer or Carcinome or Tumeur)) OR (Mélanocytes Near3 (Cancer or Carcinome or Tumeur))) | 3375 hits |
German | (Melanom or (Haut NEAR3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst)) OR (Melanozyten Near3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst))) | ||||||
3 | Final query | 1 OR 2 | 3422 hits (2023 unique records, 30-35 % relevant) |
Search in Micropatent MPI-INPADOC - English language search
Micrpatent MPI-INPADOC search bibliographic data for 71 countries and legal status for 42. Only those patents were analyzed which have English title and/or abstract.
S.No. | Search concept | Search Scope | Search reason | Class search | Search query | No. of hits |
1 | Interferon for treating Melanoma | Title and Abstract | Specific IPC classes of interferon AND melanoma keywords | A61K03821 OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 | (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 174 |
2 | Interferon for treating Melanoma | Title and Abstract | Broad IPC classes of interferon AND melanoma, interferon keywords | A61K03819 OR C07K01452 OR A61P03500 | (IFN* OR *IFN OR interferon* OR *interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 484 |
3 | Interferon for treating Melanoma | Title and Abstract | Specific ECLA classes of interferon AND melanoma keywords | A61K03821* OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 OR C07K014715G | (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 102 |
4 | Interferon for treating Melanoma | Title and Abstract | Broad ECLA classes of interferon AND melanoma, interferon keywords | A61K03819 OR C07K01452 OR A61P03500 | (IFN* OR *IFN OR interferon* OR *interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte* NEAR3 (cancer OR carcinoma OR tumor))) | 9 |
5 | Final query | 1 OR 2 OR 3 OR 4 | 587 hits 232 unique records |
Search in Micropatent MPI-INPADOC - Foreign language search
Micrpatent MPI-INPADOC search bibliographic data for 71 countries and legal status for 42. Only those patents were analyzed which have English title and/or abstract.
S.No. | Search concept | Language | Search Scope | Search reason | Class Code (IPC, ECLA) | Search query | No. of hits |
1 | Interferon for treating Melanoma | French | Title and Abstract | Specific IPC/ECLA classes of interferon AND melanoma keywords | A61K03821 OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 | (mélanome or (Peau NEAR3 (Cancer or Carcinome or Tumeur)) OR (Mélanocytes Near3 (Cancer or Carcinome or Tumeur))) | 4 hits |
German | (Melanom or (Haut NEAR3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst)) OR (Melanozyten Near3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst))) | ||||||
2 | Interferon for treating Melanoma | French | Title and Abstract | Broad IPC classes of interferon AND melanoma, interferon keywords | A61K03819 OR C07K01452 OR A61P03500 | (IFN* OR *IFN OR Interféron* OR *Interféron OR huIFN) AND (mélanome or (Peau NEAR3 (Cancer or Carcinome or Tumeur)) OR (Mélanocytes Near3 (Cancer or Carcinome or Tumeur))) | 25 hits |
German | (IFN* OR *IFN OR interferon* OR *interferon OR huIFN AND (Melanom or (Haut NEAR3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst)) OR (Melanozyten Near3 (Krebs or Karzinom or Krebsgeschwür or Tumor or Geschwulst))) | ||||||
3 | Final query | 1 OR 2 | 29 hits |
Search in Japanese database
Database: IPDL (Industrial property digital library), Japan
Date of search: 1900/01/01 to 2011/02/15
S.No. | |
|
|
|
|
|
|
|
|
Total patents: 1298 (Relevancy ~10%)
- F-Terms and theme used in search
Japanese F-term search | Definition | ||
Sr. No. | F- Term theme | 4H045 | Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof |
1 | F-term | DA15 | Peptide or protein characterised by function - Interferons |
2 | F-term | DA16 | Alpha-interferons |
3 | F-term | DA17 | Beta-interferons |
4 | F-term | DA18 | Gamma-interferons |
Scientific Literature Search
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sample patents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxonomy
Sample Analysis
- Patents: The above sample patents were analysed according to the taxonomy.
Click here to download Sample analysis sheet on Interferon for treatment of Melanomas
- Scientific Literature:* Click here to download Melanoma Treatment Using IFN: sample articles
Patent Ranking
10 Sample Patents were ranked according to the patent focus.
- Patent Ranking Details
1 : Granted Patent & Focus in Independent Claim
2 : Granted Patent & Focus in Dependent Claim
3 : Published Patent & Focus in independent Claim
4 : Published Patent & Focus in Dependent claim
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical Trials
- Database: Clinical trials
- Searched on: Feb 25th, 2011
IP Activity Graphs Of Sample Patents
IP activity based on priority years
- Total of 10 Sample patents(basic patent number) were taken into consideration for the IP activity based on priority years.
IP activity based on publication years
- Total of 10 Sample patents(basic patent number) were taken into consideration for the IP activity based on publication years.
Geographical Distribution based on family members
- The geographical distribution is based on 10 sample patent numbers along with all their family members.
Market Report
Interferon types & Their Compositions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interferon Types & Description Of Products
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Revenue Data Of products
S.No | Generic Name | Brand Name | Company | Global revenue ($ Million ) | ||
2008 | 2009 | 2010 | ||||
1 | Alpha IFN | Intron®,Roferon®-A | Schering Corporation | 38.4 2 | ||
2 | Beta IFN | Avonex | Biogen IDEC | 2518.4 | 2322.9 | 2202.6 3 |
3 | Gamma IFN | Actimmune® | Intermune | 29880 | 25428 4 | |
4 | Pegylated IFN | Peg Intron | Schering-Plough | 148.7 5 | ||
5 | Recombinant IFN | Rebetron®, Rebetol® | Schering Corporation | 36.1 |
Biosimilars Of Interferons
Biosimilar interferons are the major drug class in the recombinant non-glycosylated proteins market due to their extensive use in the treatment of various genetic and environmental disorders. The overall biosimilar market for interferons is categorized into the submarkets for alpha, beta, and gamma interferons, all of which are used extensively in the treatment of various conditions such as lymphoma, hairy cell leukemia, and multiple sclerosis.
While the interferon market growth may be inhibited by the side effects of each of its three drug categories, the market presents many opportunities to new entrants as only a few players currently operate in this relatively unfragmented market.
The global recombinant interferon market stood at $75.3 million in 2008 and is expected to reach $3.9 billion by 2014 at a CAGR of 82.9% from 2009 to 2014. The American biosimilar interferons market is expected to attain a market worth $1.5 billion by 2014 at a CAGR of 91.5%.Biosimilars ; Global Market
|
|
|
|
|
|
|
|
|
|
|
|